Extracorporeal Membrane Oxygenation Complications in Heparin- and Bivalirudin-Treated Patients.
Research article published in Critical care explorations (2021)
Abstract
UNLABELLED: Extracorporeal membrane oxygenation is a potentially life-saving intervention in refractory cardiopulmonary failure, but it requires anticoagulation to prevent circuit thromboses, which exposes the patient to hemorrhagic complications. Heparin has traditionally been the anticoagulant of choice, but the direct thrombin inhibitor bivalirudin is routinely used in cases of heparin-induced thrombocytopenia and has been suggested as a superior choice. We sought to examine the timing of hemorrhagic and thrombotic complications after extracorporeal membrane oxygenation cannulation and to compare the rates of such complications between patients anticoagulated with heparin versus bivalirudin. DESIGN: Retrospective cohort study. SETTING: Johns Hopkins Hospital patients between January 2016 and July 2019. PATIENTS: Adult (> 18 yr) extracorporeal membrane oxygenation patients. INTERVENTIONS: Patients were anticoagulated either with heparin or bivalirudin. MEASUREMENTS AND MAIN RESULTS: We compared rates of hemorrhagic and thrombotic complications by time on heparin versus bivalirudin and characterized the average time to each complication. Of 144 extracorporeal membrane oxygenation patients (mean age 55.3 yr; 58% male), 41% were on central venoarterial extracorporeal membrane oxygenation, 40% on peripheral venoarterial extracorporeal membrane oxygenation, and 19% on venovenous extracorporeal membrane oxygenation. Thirteen patients (9%) received bivalirudin during their extracorporeal membrane oxygenation run, due to concern for (n = 8) or diagnosis of (n = 4) heparin-induced thrombocytopenia or for heparin resistance (n = 1). The rate of hemorrhagic or thrombotic complications did not differ between heparin (0.13/d) and bivalirudin (0.06/d; p = 0.633), but patients on bivalirudin received significantly fewer blood transfusions (1.0 U of RBCs/d vs 2.9/d on heparin; p < 0.001). CONCLUSIONS: Our results confirm the safety and efficacy of bivalirudin as an alternative anticoagulant in extracorporeal membrane oxygenation and suggest a potential benefit in less blood product transfusion, although prospective studies are needed to evaluate the true effect of bivalirudin versus the disease processes that prompted its use in our study population.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Zusammenfassung
Extracorporeal membrane oxygenation is a potentially life-saving intervention in refractory cardiopulmonary failure, but it requires anticoagulation to prevent circuit thromboses, which exposes the patient to hemorrhagic complications. Heparin has traditionally been the anticoagulant of choice, but...
Warum dies für die Hirudotherapie relevant ist
Diese retrospektive Kohortenstudie untersuchte Zeitpunkt und Raten hämorrhagischer und thrombotischer Komplikationen bei 144 erwachsenen ECMO-Patientinnen und -Patienten, die am Johns Hopkins Hospital (Januar 2016–Juli 2019) entweder mit Heparin oder Bivalirudin antikoaguliert wurden. Es wurde kein signifikanter Unterschied bei den täglichen Komplikationsraten zwischen Heparin (0,13/d) und Bivalirudin (0,06/d; p=0,633) beobachtet, wobei Patientinnen und Patienten unter Bivalirudin jedoch signifikant weniger Erythrozytenkonzentrat-Transfusionen erhielten (1,0 E/d vs. 2,9/d; p<0,001). Diese Studie weist keine vertretbare Verbindung zur Hirudotherapie, Blutegeltherapie oder zum Blutegel-Sekretom auf: Das Abstract identifiziert Bivalirudin ausschließlich als direkten Thrombininhibitor und enthält keinerlei Bezug auf Hirudin, Blutegel oder Blutegel-abgeleitete Verbindungen. Einschränkung: Die kleine Bivalirudin-Subgruppe (n=13) begrenzt die Aussagekraft des Vergleichs, und die Autorinnen und Autoren fordern prospektive Studien.
Zitation
Extracorporeal Membrane Oxygenation Complications in Heparin- and Bivalirudin-Treated Patients.
Giuliano et al. · Critical care explorations, 2021
Verwandter klinischer Kontext
Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist
Zur ASH-Bibliothek hinzugefügt: May 28, 2026 · Letzte Aktualisierung der Website: 18. Juni 2026